机构:[1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, Sichuan, China.[3]Laboratory for Targeted Radiopharmaceuticals Creation, Southwest Medical University, Luzhou, Sichuan, China.[4]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
第一作者机构:[1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, Sichuan, China.[3]Laboratory for Targeted Radiopharmaceuticals Creation, Southwest Medical University, Luzhou, Sichuan, China.[4]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
通讯作者:
通讯机构:[1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, Sichuan, China.[3]Laboratory for Targeted Radiopharmaceuticals Creation, Southwest Medical University, Luzhou, Sichuan, China.[4]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
推荐引用方式(GB/T 7714):
Ma Jiao,Zhang Yu,Yangqing Jiangchu,et al.The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer[J].Frontiers In Oncology.2025,15:1516860.doi:10.3389/fonc.2025.1516860.
APA:
Ma Jiao,Zhang Yu,Yangqing Jiangchu,Liu Guangfu,Wang Junzheng&Zhang Chunyin.(2025).The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer.Frontiers In Oncology,15,
MLA:
Ma Jiao,et al."The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer".Frontiers In Oncology 15.(2025):1516860